Semaglutide shows strong weight loss in adolescents but lacks long-term safety data on bone and growth
A study presented at a medical conference found that the GLP-1 medication semaglutide produces substantial weight loss in adolescents with obesity, with similar gastrointestinal side effects as seen in adults. However, researchers noted that trials in teens rarely assess critical developmental factors including bone density, lean mass, or neurodevelopment.
